Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bambermycins** are a fermentation-derived phosphoglycolipid antibiotic complex used exclusively in veterinary animal nutrition as an in-feed performance enhancer. The complex, also called flavophospholipol, acts predominantly against Gram-positive bacteria by inhibiting bacterial peptidoglycan glycosyltransferases, thereby blocking cell-wall glycan-chain synthesis. In the United States, bambermycins Type A medicated articles are approved for use in broiler chickens, growing turkeys, growing-finishing swine, and cattle to improve feed efficiency and or rate of weight gain. ([ecfr.gov](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-E/part-558/subpart-B/section-558.95))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bambermycins.